EPS: As of FY2025 Q1, the actual value is USD -1.04.

EBIT: As of FY2025 Q1, the actual value is USD -3.803 M.

Segment Revenue

• Clinical Operations: $1,107,474 for the three months ended March 31, 2025, compared to $1,077,190 for the same period in 2024, representing a 2.9% increase.
• Drug Manufacturing and Formulation: $380,353 for the three months ended March 31, 2025, compared to $341,199 for the same period in 2024, representing an 11.4% increase.

Operational Metrics

• Net Loss: $3,802,691 for the three months ended March 31, 2025, compared to $2,972,477 for the same period in 2024, representing a 28.0% increase.
• Operating Loss: $3,706,035 for the three months ended March 31, 2025, compared to $2,948,217 for the same period in 2024, representing a 25.7% increase.

Cash Flow

• Net Cash Used in Operating Activities: - $4,608,282 for the three months ended March 31, 2025, compared to - $8,746,360 for the same period in 2024.
• Net Cash Provided by Financing Activities: $1,915,927 for the three months ended March 31, 2025, compared to $9,889,283 for the same period in 2024.

Unique Metrics

• Stock-Based Compensation Expense: $357,649 for the three months ended March 31, 2025, compared to $164,575 for the same period in 2024.

Future Outlook and Strategy

• Core Business Focus: The company plans to file its NDA submission for CTx-1301 in mid-2025 and believes its cash will satisfy capital needs into the fourth quarter of 2025 under the current business plan.
• Non-Core Business: The company received a grant of $3 million to support the clinical and manufacturing development of CTx-2103, with payments contingent on specific milestones.

Priority

• The company is actively seeking strategic partnerships for licensing CTx-1301 in the United States and internationally, and has entered into a master services agreement with Indegene for commercialization services.